Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Total Non-Current Liabilities (2016 - 2022)

Historic Total Non-Current Liabilities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $152.5 million.

  • Avadel Pharmaceuticals' Total Non-Current Liabilities fell 537.57% to $152.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $152.5 million, marking a year-over-year decrease of 537.57%. This contributed to the annual value of $165.1 million for FY2021, which is 1374.01% up from last year.
  • As of Q3 2022, Avadel Pharmaceuticals' Total Non-Current Liabilities stood at $152.5 million, which was down 537.57% from $155.6 million recorded in Q2 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Total Non-Current Liabilities peaked at $250.6 million during Q1 2018, and registered a low of $145.2 million during Q4 2020.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $165.1 million (2021), whereas its average is $169.9 million.
  • Per our database at Business Quant, Avadel Pharmaceuticals' Total Non-Current Liabilities soared by 2907.36% in 2018 and then crashed by 3190.04% in 2019.
  • Quarter analysis of 5 years shows Avadel Pharmaceuticals' Total Non-Current Liabilities stood at $173.5 million in 2018, then dropped by 1.01% to $171.8 million in 2019, then dropped by 15.49% to $145.2 million in 2020, then grew by 13.74% to $165.1 million in 2021, then fell by 7.65% to $152.5 million in 2022.
  • Its last three reported values are $152.5 million in Q3 2022, $155.6 million for Q2 2022, and $162.0 million during Q1 2022.